Amyl Therapeutics
Personen
7
Locaties
1
Publicaties
13
Bedrijfsprofiel
Oprichtingsdatum
26 november 2020
Laatste Balansjaar
2024
Rechtsvorm
Besloten Vennootschap
Ondernemingstype
Rechtspersoon
Activiteit
72101 - Speur- en ontwikkelingswerk op biotechnologisch gebied
Leeftijd Onderneming
6 jaar
Contactgegevens
Unlock direct contact points, registry address detail, and website links for Amyl Therapeutics.
Unlock Contact Details
Reveal email, phone, website, and full registry contact information.
Create Free AccountHistorische Financiële Gegevens
| KPI | 2024 | 2023 | 2022 |
|---|---|---|---|
| Omzet | - | - | - |
| Brutomarge | € -872.434 (-29.4%) | € -674.399 (+19.8%) | € -840.592 (+3.9%) |
| Winst | € -2.436.601 (-42.5%) | € -1.709.641 (-20.8%) | € -1.415.300 (-41.6%) |
| EBITDA | € -12.586 (-105.4%) | € 231.272 (+218.5%) | € -195.232 (+70.9%) |
| Eigen Vermogen | € 5.562.413 (-30.5%) | € 7.999.014 (+28.8%) | € 6.208.656 (-18.6%) |
| Schulden | € 2.682.460 (+178.0%) | € 964.985 (+95.4%) | € 493.938 (-54.9%) |
| Totaal Activa | € 8.385.696 (-6.5%) | € 8.963.999 (+33.7%) | € 6.702.593 (-23.2%) |
| Kasmiddelen | € 2.283.118 (-26.1%) | € 3.089.277 (+106.7%) | € 1.494.636 (-58.7%) |
| VTE (FTE) | 4,6 (0.0%) | 4,6 (+100.0%) | 2,3 (+228.6%) |
Unlock Full History
Create a free account to access up to 10 years of historical financial data for Amyl Therapeutics.
Create Free AccountFinanciële Gezondheid
Ratio-level insight derived from the latest company and balance sheet data.
Current Ratio
5,3x
(+30.0%)
Quick Ratio
5,3x
(+30.0%)
Solvency
66,3%
(-25.7%)
Debt / Equity
0,5x
Unlock Advanced Metrics
Access the full ratio deck, benchmarking signals, and deeper profitability diagnostics.
Create Free AccountVestigingen & Voetafdruk
Establishment
AdresBoulevard de Patience et Beaujonc 3, 4000 Luik, Belgium
Bedrijfsnetwerk
First-level relations linked directly to Amyl Therapeutics. Unlock second-level relations for deeper graph exploration.
Amyl Therapeutics
Actief
- NOSHAQ
Incoming link
Administrator Legal - NOSHAQ PARTNERS
Incoming link
Administrator Legal - VACCIBIO CONSULTING
Incoming link
Administrator Legal -
Kenneth BUCKFIRE
Incoming link
Administrator Natural -
Valérie CALENDA
Incoming link
Administrator Natural - NOSHAQ
Outgoing link
Participating Interest - VACCIBIO CONSULTING
Outgoing link
Participating Interest - 6K venture capital
Incoming link
Shareholder Entity - NOSHAQ
Incoming link
Shareholder Entity - VACCIBIO CONSULTING
Incoming link
Shareholder Entity -
Evren Uçok
Incoming link
Shareholder Individual -
Kenneth BUCKFIRE
Incoming link
Shareholder Individual -
Amel TOUNSI
Incoming link
Administrator Legal Representative -
GROS FLORENT
Incoming link
Administrator Legal Representative -
Hélène SABATEL
Incoming link
Administrator Legal Representative -
Pierre Vandepapeliere
Incoming link
Administrator Legal Representative
Unlock Second-Level Relations
Expand beyond direct links to see second-level entities, people, and cross-company paths.
Free Sign UpPublicaties in het Belgisch Staatsblad
Management & Sleutelfiguren
Unlock linked people, governance roles, and enriched demographic signals associated with Amyl Therapeutics.
Management Profiles
Unlock directors, managers, role history, plus inferred gender and age where available.
Create Free Account